Important Notes
Applicants are strongly advised to read the instructions and eligibility criteria before starting an application.
If you should experience any technical difficulties during the application process please contact the ATS Research Program
Anticipated Timeline
| Monday, July 17, 2023 | Grant Portfolio Opens at 9:00 AM EST |
| Monday, January 8, 2024 | Full Applications Due by 11:59 PM EST |
| March 2024 | Grantee Notification |
| May 2024 | Grant Start Date |
Partner Grant Opportunities
ALA/ATS/CHEST Foundation Respiratory Health Equity Research Award
1 grant available
$100,000 per year for 2 years
Target Audience:
Early-stage investigator who is addressing topics on improving clinical outcomes in preventing and/or treating lung disease in groups disproportionately impacted.
The focus of this research grant is clinical research that addresses topics on improving clinical outcomes in preventing and/or treating lung disease that disproportionately affects under-represented minority (URM) patient groups. URM patient groups includes patients from lower-middle- and low-income countries as defined by the World Bank, or the following North American populations: African Americans, Mexican-Americans, Native Americans (American Indians, Alaska Natives, and Native Hawaiians), Pacific Islanders, and mainland Puerto Ricans.
Applicants may request up to $100,000 per year for two years for salaries, supplies, or a combination of these two. No more than 20% of the budget can be for salary. Indirect costs will not be paid to the sponsoring institution.
Recipients will also be eligible for complimentary registration and a $1,000 travel stipend to attend both the ATS International Conference and CHEST Annual Meeting up to one-year past conclusion of the research to present data.
Award-specific eligibility:
- Must be US citizens or hold a Visa that spans the project period of the grant
- Early-stage investigators (as defined here) and applicants who are trainees (fellows)
- Applicants holding PhD, MD, RN, RRT, or PA degrees
- Must be a member of both the ATS and CHEST
- Must meet eligibility requirements for all grants found here
Co-funded by the American Lung Association, ATS, and the CHEST Foundation.
ATS/Alveolar Capillary Dysplasia (ACDMPV) Research Grant
1 grant available
$50,000 per year for 2 years
Target Audience:
The target group for the research grant will be investigators at any stage of their academic career interested in ACDMPV research.
The focus of this research grant is proposals that advance research in the area of alveolar capillary dysplasia with misalignment of the pulmonary veins (ACDMPV). Proposals may be basic, translational, or clinical science research projects. Procedures or proposed therapeutic trials may be new, based on recent biochemical or pharmacological evidence, or in preliminary stages of clinical investigation.
Co-funded by the ACDA and The David Ashwell Foundation.
The ACDA and The David Ashwell Foundation are respectively USA- and UK-based not for profit charitable organizations founded by parents of infants with ACDMPV. Funds are raised by parents, families, and friends globally with the aim of increasing scientific knowledge about ACDMPV and therapeutic strategies related thereto.
ATS/CSL Behring Research Award in Acute Respiratory Distress Syndrome (ARDS)
1 grant available
$50,000 per year for 1 year
Target Audience:
Early-stage investigators interested in research on ARDS.
The focus of this research grant is proposals that advance understanding of acute respiratory distress syndrome (ARDS). Applicants may request up to $50,000 for 1 year. Granted funds may be used to provide salary support for the PI or ancillary staff, to purchase supplies and/or reagents, or subject enrollment fees directly related to the project or other allowable costs. Travel for the PI for purposes of presenting data related to the project is limited to $2,000 per year. Indirect costs will not be paid to the sponsoring institution.
Award-specific eligibility:
• Early-stage investigators (as defined here)
• Must meet eligibility requirements for all grants found here
Fully funded by CSL Behring.
ATS/Fisher & Paykel Healthcare Research Grant in Nasal High Flow
1 grant available
$50,000 per year for 2 years
|
Target Audience: |
|
The focus of this research grant is proposals on respiratory support with nasal high flow therapy in stable, adult patients. Patients must be in the hospital care during their involvement in the project. Nasal high flow (NHF) therapy refers to a typical range from 20 to 70 L/min of heated, humidified air with or without supplemental oxygen delivered to the nares via the purposely designed nasal cannula interface. Nasal high flow (NHF) therapy refers to a typical range from 20 to 70 L/min of heated, humidified gas delivered to the nares via purposely designed nasal cannula. Flow settings and fraction of delivered supplemental oxygen during the therapy vary depending on the patient’s level of compliance and severity of disease. There has been a recent rapid uptake in the use of NHF in acute care settings, primarily to treat hypoxemic respiratory failure, and the therapy has been extensively used around the world during the COVID-19 pandemic. Apart from efficient oxygenation due to the prevention of room air entrainment, NHF provides respiratory support that may be seen in the reduction of the breathing frequency and the work of breathing. Positive airway pressure and the reduction of re-breathing caused by the clearance of expired gas in the upper airways are believed to be the key mechanisms that may improve the ventilation efficiency during NHF. Saturation with water of heated gas maintains hydration of the airway surface liquid and preserves mucociliary function. NHF therapy is increasingly used in stable patients with lung disease or post-surgery who require support during unassisted breathing with little or no supplemental oxygen. Fisher & Paykel Healthcare, in collaboration with the American Thoracic Society, seeks to offer a research award to investigators interested in studying these potential benefits of NHF in hospital patients. The prospective study could be aimed at better understanding the mechanisms of action of this therapy, or on achieving improvements in a variety of likely outcomes. Applicants may request up to $50,000 per year for 2 years. NHF equipment and consumables can be provided for the study by Fisher & Paykel Healthcare at no cost. Granted funds may be used to provide salary support for the PI or ancillary staff, to purchase supplies and/or reagents, or subject enrollment fees directly related to the project or other allowable costs. Travel for the PI for purposes of presenting data related to the project is limited to $2,000 per year. Indirect costs will not be paid to the sponsoring institution. |
|
Fully funded by Fisher & Paykel Healthcare. |
The Hermansky-Pudlak Syndrome Network Inc. Research Grant in Immune Responses in HPS-ILD
1 grant available – 40,000 per year for 2 years
Target Audience:
The target group for the research grant will be investigators interested in investigating the pivotal role of immune cells in understanding the underlying mechanisms of immune responses in HPS-ILD with the goal of fostering development of novel therapeutic approaches for the management of HPS-ILD.
The focus of this research grant is on advancing knowledge and understanding of the immune mechanisms underlying Hermansky-Pudlak Syndrome-Interstitial Lung Disease (HPS-ILD). This grant aims to provide support for innovative research projects that investigate the pivotal role of immune cells in understanding the underlying mechanisms of immune responses in HPS-ILD. Additionally, it aims to foster the development of novel therapeutic approaches for the management of HPS-ILD.
Review Process
Please note that after you submit your application it will be reviewed by Research Program staff. If there are any problems or if these guidelines have not been followed, your proposal will be un-submitted. Please make sure that you check your email after you submit your application so that any outstanding issues may be addressed as quickly as possible.
The ATS Scientific Grant Review Committee (SGRC)* will review the applications at the end of February 2023. The membership of the SGRC is listed on the ATS Website and additional ad hoc reviewers will be invited to participate as needed. Funding decisions will be made on the basis of scientific merit, novelty, and responsiveness to the purpose of the specific grant program.
*previously known as the Scientific Advisory Committee (SAC)
ATS Policy on Additional Grant Funding
Simultaneous submission of grants with scientific overlap is allowed, but if multiple applications are funded, then the applicant must notify the Research Program within one month of formal notification of award. A subcommittee of the SGRC will assess the degree of overlap. In the case of significant scientific overlap, the applicant will have to choose between the ATS Foundation research grant and the other grant. Budgetary overlap is not allowed.
If your question is not answered in the FAQ, please contact the ATS Research Program.
